BioGeneration Ventures logo

BioGeneration Closes Fund to Support Early Stage Biotech Startups

BioGeneration Ventures (BGV), a leading early-stage venture capital firm in European biopharma, has closed its fifth fund, BGV V, at €150 million ($167.9 million). BGV V was oversubscribed, with demand from both existing and new investors.

BioGeneration Ventures logo

The fund will be used to support early-stage biotech startups in Europe. BGV is targeting companies that are developing novel therapies for unmet medical needs.

The firm has a strong track record of investing in and building successful biotech companies.

BGV’s portfolio companies include Acerta Pharma, which was acquired by AstraZeneca for approximately $7 billion, and Synaffix, which was acquired by Lonza for €160 million. BGV also has a number of other portfolio companies that are in clinical development.

“We are excited to close BGV V at this level,” said Edward van Wezel, Managing Partner at BGV. The strong demand for the fund is a validation of our investment strategy and our team’s track record. We look forward to using Fund V to invest in and build the next generation of European biotech leaders.”

BGV is well-positioned to support the growth of the European biotech industry. The firm has a strong team of experienced investment professionals with a deep understanding of the industry. BGV is also well-connected to the European biotech ecosystem.

The closing of BGV V is a significant milestone for the firm. The fund will help BGV to continue its track record of investing in and building successful biotech companies.

Here are some of the reasons why BioGeneration Ventures was able to close Fund V:

  • The firm has a strong track record: BGV has a long track record of investing in and building successful biotech companies. Its portfolio companies have consistently outperformed the market.
  • The firm has a strong team: BGV has a team of experienced investment professionals with a deep understanding of the biotech industry.
  • The firm is targeting attractive sectors: BGV is targeting attractive sectors, such as cancer, rare diseases, and immunology. These sectors are expected to grow significantly in the coming years.
  • The firm is offering attractive terms: BGV is offering attractive terms to its investors, such as a high-water mark provision and a carry kicker.

Notice: ob_end_flush(): Failed to send buffer of zlib output compression (1) in /home/rainmak1/public_html/wp-includes/functions.php on line 5420

Notice: ob_end_flush(): Failed to send buffer of zlib output compression (1) in /home/rainmak1/public_html/wp-includes/functions.php on line 5420